Your browser doesn't support javascript.
loading
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal, Neeraj; Azad, Arun A; Carles, Joan; Fay, Andre P; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; De Giorgi, Ugo; Young Joung, Jae; Fong, Peter C C; Voog, Eric; Jones, Robert J; Shore, Neal D; Dunshee, Curtis; Zschäbitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim.
Afiliación
  • Agarwal N; Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.
  • Azad AA; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Carles J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fay AP; PUCRS School of Medicine, Porto Alegre, Brazil.
  • Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
  • Heinrich D; Innlandet Hospital Trust, Gjøvik, Norway.
  • Szczylik C; Department of Oncology, European Health Center, Otwock, Poland; Postgraduate Medical Education Center, Warsaw, Poland.
  • De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
  • Young Joung J; National Cancer Center, Goyang, South Korea.
  • Fong PCC; Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand.
  • Voog E; Clinique Victor Hugo Centre Jean Bernard, Le Mans, France.
  • Jones RJ; School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
  • Dunshee C; Arizona Urology Specialists, Tucson, AZ, USA.
  • Zschäbitz S; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Oldenburg J; Akershus University Hospital (Ahus), Lørenskog, Norway.
  • Lin X; Pfizer, La Jolla, CA, USA.
  • Healy CG; Pfizer, Collegeville, PA, USA.
  • Di Santo N; Pfizer, Durham, NC, USA.
  • Zohren F; Pfizer, New York, NY, USA.
  • Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
Lancet ; 402(10398): 291-303, 2023 07 22.
Article en En | MEDLINE | ID: mdl-37285865
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Anemia Tipo de estudio: Clinical_trials Límite: Adolescent / Humans / Male Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Anemia Tipo de estudio: Clinical_trials Límite: Adolescent / Humans / Male Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article